ValiRx (VAL) has been granted a patent from the European Patent Office for its pre-clinical therapeutic compound, VAL301, subject to the company paying relevant fees.
This EU patent marks ValiRx latest protections in a significant and populous market, building on their patents in the United States, granted last year, China, and Russia, announced earlier this year.
Shares in ValiRx are up nearly 6% following the news.
VAL301 is currently in late-stage pre-clinical development as a “non-invasive, effective treatment for the non-cancerous, but hugely debilitating gynaecological condition, endometriosis.”
Dr Satu Vainikka, CEO of ValiRx plc, commented: "This is excellent news and I am delighted that the patent portfolio for our lead compounds continues to strengthen, add value and receive further endorsement.
For more news and updates on ValiRx: